MISSISSAUGA, Ontario, Aug. 02, 2018 (GLOBE NEWSWIRE) -- Hydrogenics Corporation (NASDAQ:HYGS) (TSX:HYG) ("Hydrogenics" or "the Company"), a leading developer and manufacturer of hydrogen generation and hydrogen-based power modules, today reported second quarter 2018 financial results. Results are reported in US dollars and are prepared in accordance with International Financial Reporting Standards (IFRS).

Recent Highlights

“While top line results reflected continued lumpiness in orders and delivery timing, gross margins rose significantly year-over-year, reflecting improved product mix as well as our focus on supply chain management and ongoing efficiency initiatives,” said Daryl Wilson, President and Chief Executive Officer. “Our backlog remains solid and the outlook strong as we prepare for anticipated increases in product shipments to China during the second half of 2018. Notably, we also made advances in the quarter expanding our technology penetration into new markets, securing our first development contract for a high-speed marine application. We are delighted to partner with Golden Gate Zero Emission Marine on this important endeavor, which complements and bolsters our existing leadership position providing fuel cell modules for rail, bus and other heavy-duty power systems.

“In addition to the progress experienced in our mobility business, we continue to see momentum across a variety of other renewable hydrogen applications, including energy storage. The impetus of positive regulatory changes, such as the June 15 adoption of the EU’s Renewable Energy Directive Part ii, is driving significant activity within our sales pipeline for large Power-to-Gas projects in the 10-25 MW scale. We remain convinced that the unmatched energy density and size advantage of our industry-leading PEM electrolyzer technology positions us well for these opportunities, and we now have a showcase site – with Enbridge – up and running in North America. Given our unique leadership in the space, increasing demand within the markets where we operate, and our strong relationships with customers and partners worldwide, we're optimistic about the quarters to come.”

Summary of Results for the Quarter Ended June 30, 2018

-- The Company posted revenue of $7.6 million for the second quarter of 2018, comparable to the same period last year. -- Gross margin improved to 27.6% in the second quarter of 2018 compared with to 5.8% last year, as the Company posted gross profit of $2.1 million in the current quarter versus $0.4 million in the prior-year period. The higher gross margin was achieved via cost reductions secured through our supply chain, process efficiency improvements as well as product mix. -- Cash operating costs1 increased $0.7 million to $4.6 million in the 2018 second quarter compared to $3.9 million in 2017 due to $0.4 million of higher net research and development (“R&D”) expenses, primarily related to ongoing product development initiatives and $0.3 million of higher selling expenses related to a refreshed corporate branding, marketing and business development. -- The Company’s Adjusted EBITDA2 loss improved $1.0 million to $2.4 million in the second quarter of 2018 from $3.4 million in the prior-year period. This variance reflects the increase in gross profit offset by higher cash operating costs noted above. -- Net loss decreased from $5.5 million, or $(0.43) per share, to $4.8 million, or $(0.31) per share, in the current period, primarily due to the increase in gross profit, offset by the increase in net R&D expenses, losses from our joint venture investments and the increase in SG&A net of non-cash gains from revaluation of deferred stock unit (“DSU”) obligations. -- The Company ended the second quarter of 2018 with the backlog at $131.8 million, securing orders of $10.7 million for Power-to-Gas systems, fueling stations, industrial gas applications and mobility systems. Order backlog movement during the second quarter (in $ millions) was as follows:

March 31, Orders FX Orders Delivered/ Orders Cancelled June 30, 2018 backlog Received Revenue Recognized 2018 backlog ----------------- - ------------ - -------- - ---- - - ------------------ - ---------------- - ------------ OnSite Generation $ 17.3 $ 8.1 $ (0.1 ) $ 4.8 $ - $ 20.5 Power Systems 122.8 2.6 (3.8 ) 2.8 7.5 111.3 ----------------- - ------------ - -------- - ---- - - ------------------ - ---------------- - ------------ Total $ 140.1 $ 10.7 $ (3.9 ) $ 7.6 $ 7.5 $ 131.8 ----------------- - ------------ - -------- - ---- - - ------------------ - ---------------- - ------------

-- Of the above backlog of $131.8 million, the Company expects to recognize $51.8 million in the following 12 months as revenue. In addition, revenue for the year ending December 31, 2018 will also include orders both received and delivered during the balance of 2018.

Notes

1. Cash operating costs are defined as the sum of SG&A and R&D, less amortization and depreciation, and stock-based compensation expense inclusive of compensation costs indexed to the Company’s share price. This is a non-IFRS measure and may not be comparable to similar measures used by other companies. Management uses this measure as a rough estimate of the amount of fixed costs to operate the Corporation and believes this is a useful measure for investors for the same purpose.

2. Adjusted EBITDA is defined as net loss excluding stock-based compensation (both cash settled long term compensation indexed to share price and share based compensation), other finance income and expenses, depreciation and amortization. These items are considered by management to be outside of Hydrogenics’ ongoing operational results. Adjusted EBITDA is a non-IFRS measure and may not be comparable to similar measures used by other companies.

Conference Call DetailsHydrogenics will hold a conference call at 10:00 a.m. EDT on August 2, 2018 to review the second quarter results. The telephone number for the conference call is (877) 307-1373 or, for international callers, (678) 224-7873. A live webcast of the call will also be available on the company's website, www.hydrogenics.com.

An archived copy of the conference call and webcast will be available on the company's website, www.hydrogenics.com, approximately six hours following the call.

About Hydrogenics Hydrogenics Corporation is a world leader in engineering and building the technologies required to enable the acceleration of a global power shift. Headquartered in Mississauga, Ontario, Hydrogenics provides hydrogen generation, energy storage and hydrogen power modules to its customers and partners around the world. Hydrogenics has manufacturing sites in Germany, Belgium and Canada and service centers in Russia, Europe, the US and Canada.

Forward-looking StatementsThis release contains forward-looking statements within the meaning of the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995, and under applicable Canadian securities law. These statements are based on management’s current expectations and actual results may differ from these forward-looking statements due to numerous factors, including: our inability to increase our revenues or raise additional funding to continue operations, execute our business plan, or to grow our business; inability to address a slow return to economic growth, and its impact on our business, results of operations and consolidated financial condition; our limited operating history; inability to implement our business strategy; fluctuations in our quarterly results; failure to maintain our customer base that generates the majority of our revenues; currency fluctuations; failure to maintain sufficient insurance coverage; changes in value of our goodwill; failure of a significant market to develop for our products; failure of hydrogen being readily available on a cost-effective basis; changes in government policies and regulations; failure of uniform codes and standards for hydrogen fueled vehicles and related infrastructure to develop; liability for environmental damages resulting from our research, development or manufacturing operations; failure to compete with other developers and manufacturers of products in our industry; failure to compete with developers and manufacturers of traditional and alternative technologies; failure to develop partnerships with original equipment manufacturers, governments, systems integrators and other third parties; inability to obtain sufficient materials and components for our products from suppliers; failure to manage expansion of our operations; failure to manage foreign sales and operations; failure to recruit, train and retain key management personnel; inability to integrate acquisitions; failure to develop adequate manufacturing processes and capabilities; failure to complete the development of commercially viable products; failure to produce cost-competitive products; failure or delay in field testing of our products; failure to produce products free of defects or errors; inability to adapt to technological advances or new codes and standards; failure to protect our intellectual property; our involvement in intellectual property litigation; exposure to product liability claims; failure to meet rules regarding passive foreign investment companies; actions of our significant and principal shareholders; dilution as a result of significant issuances of our common shares and preferred shares; inability of US investors to enforce US civil liability judgments against us; volatility of our common share price; and dilution as a result of the exercise of options. Readers should not place undue reliance on Hydrogenics’ forward-looking statements. Investors are encouraged to review the section captioned “Risk Factors” in Hydrogenics’ regulatory filings with the Canadian securities regulatory authorities and the US Securities and Exchange Commission for a more complete discussion of factors that could affect Hydrogenics’ future performance. Furthermore, the forward-looking statements contained herein are made as of the date of this release, and Hydrogenics undertakes no obligations to revise or update any forward-looking statements in order to reflect events or circumstances that may arise after the date of this release, unless otherwise required by law. The forward-looking statements contained in this release are expressly qualified by this.

Hydrogenics Contacts:

Marc Beisheim, Chief Financial OfficerHydrogenics Corporation(905) 361-3660 investors@hydrogenics.com

Chris WittyHydrogenics Investor Relations(646) 438-9385 cwitty@darrowir.com

Reconciliation of Cash Operating Costs to Operating Costs and Adjusted EBITDA to Net Loss (in thousands of US dollars) (unaudited) Cash operating costs Three months ended Six months ended June 30, June 30, 2018 2017 Restated 2018 2017 Restated -------------------------------------------- - ----- - - ------------- - - ----- - - ------------- - Selling, general and administrative expenses $ 3,024 $ 3,243 $ 5,860 $ 6,269 Research and product development expenses 1,880 1,492 3,961 2,497 -------------------------------------------- - ----- - - -------------- - - ----- - - ------------- - Total operating costs $ 4,904 $ 4,735 $ 9,821 $ 8,766 Less: Amortization and depreciation (89 ) (107 ) (192 ) (213 ) Less: DSUs recovery (expense) 62 (459 ) 388 (724 ) Less: Stock-based compensation expense (243 ) (189 ) (465 ) (340 ) Less: Loss on disposal of assets (3 ) (3 ) (6 ) (114 ) -------------------------------------------- - ----- - - -------------- - - ----- - - ------------- - Cash operating costs $ 4,631 $ 3,977 $ 9,546 $ 7,375 -------------------------------------------- - ----- - - -------------- - - ----- - - ------------- -

Adjusted EBITDA Three months ended Six months ended June 30 June 30, 2018 2017 Restated 2018 2017 Restated -------------------------------- - ------ - - ------------- - - ------ - - ------------- - Net loss $ (4,801 ) $ (5,462 ) $ (6,755 ) $ (7,760 ) Finance loss, net 1,998 1,167 1,973 2,107 Income tax expense - - 300 - Amortization and depreciation 175 202 352 401 DSUs expense (recovery) (62 ) 459 (388 ) 724 Stock-based compensation expense 243 189 465 340 -------------------------------- - ------ - - ------------- - - ------ - - ------------- - Adjusted EBITDA $ (2,447 ) $ (3,446 ) $ (4,053 ) $ (4,188 ) -------------------------------- - ------ - - ------------- - - ------ - - ------------- - Note: Prior period results restated to reflect the implementation of IFRS 15 revenue standard.

Hydrogenics Corporation Condensed Interim Consolidated Balance Sheets (in thousands of US dollars) (unaudited) ------------------------------------------------------------------ December 31, June 30, 2017 2018 Restated ------------------------------------ - -------- - - ------------ - Assets Current assets Cash and cash equivalents $ 13,847 $ 21,511 Restricted cash 875 435 Trade and other receivables 7,900 8,736 Contract assets 4,560 6,578 Inventories 18,501 15,048 Prepaid expenses 1,174 1,374 ------------------------------------ - -------- - - ------------ - 46,857 53,682 Non-current assets Restricted cash 281 468 Contract assets 2,409 645 Investment in joint ventures 1,121 2,797 Property, plant and equipment 3,889 3,874 Intangible assets 150 180 Goodwill 4,442 4,569 ------------------------------------ - -------- - - ------------ - 12,292 12,533 ------------------------------------ - -------- - - ------------ - Total assets $ 59,149 $ 66,215 ------------------------------------ - -------- - - ------------ - Liabilities Current liabilities Operating borrowings $ – $ 1,200 Trade and other payables 7,705 10,361 Contract liabilities 12,179 11,821 Financial liabilities 4,447 4,913 Warranty provisions 961 1,174 Deferred funding 3,514 880 28,806 30,349 Non-current liabilities Other liabilities 7,618 8,516 Contract liabilities 4,181 2,223 Warranty provisions 747 921 Deferred funding 472 33 ------------------------------------ - -------- - - ------------ - 13,018 11,693 ------------------------------------ - -------- - - ------------ - Total liabilities 41,824 42,042 ------------------------------------ - -------- - - ------------ - Equity Share capital 387,843 387,746 Contributed surplus 20,253 19,885 Accumulated other comprehensive loss (2,380 ) (1,822 ) Deficit (388,391 ) (381,636 ) ------------------------------------ - -------- - - ------------ - Total equity 17,325 24,173 ------------------------------------ - -------- - - ------------ - Total equity and liabilities $ 59,149 $ 66,215 ------------------------------------ - -------- - - ------------ - Note: Prior period results restated to reflect the implementation of IFRS 15 revenue standard.

Hydrogenics Corporation Condensed Interim Consolidated Statements of Operations and Comprehensive Loss (in thousands of US dollars, except share and per share amounts) (unaudited) ------------------------------------------------------------------------------------------------------------ Three months ended Six months ended June 30, June 30, 2018 2017 Restated 2018 2017 Restated ------------------------------------------------------- - ------ - - ------------- - - ------ - - -------- - Revenues $ 7,609 $ 7,556 $ 15,756 $ 16,291 Cost of sales 5,508 7,116 10,417 13,178 ------------------------------------------------------- - ------ - - ------------- - - ------ - - -------- - Gross profit 2,101 440 5,339 3,113 ------------------------------------------------------- - ------ - - ------------- - - ------ - - -------- - Operating expenses Selling, general and administrative expenses 3,024 3,243 5,860 6,269 Research and product development expenses 1,880 1,492 3,961 2,497 4,904 4,735 9,821 8,766 ------------------------------------------------------- - -------- - --------------- - -------- - ---------- Loss from operations (2,803 ) (4,295 ) (4,482 ) (5,653 ) ------------------------------------------------------- - ------ - - ------------- - - ------ - - -------- - Finance income (loss) Interest expense, net of financial instruments measured (372 ) (454 ) (753 ) (923 ) at amortized cost Foreign currency (losses) gains, net (177 ) 394 42 455 Loss on joint ventures (1,492 ) (101 ) (1,561 ) (171 ) Other finance gains (losses), net 43 (1,006 ) 299 (1,468 ) ------------------------------------------------------- - ------ - - ------------- - - ------ - - -------- - Finance loss, net (1,998 ) (1,167 ) (1,973 ) (2,107 ) ------------------------------------------------------- - ------ - - ------------- - - ------ - - -------- - Loss before income taxes (4,801 ) (5,462 ) (6,455 ) (7,760 ) Income tax expense – – 300 – ------------------------------------------------------- - ------ - - ------------- - - ------ - - -------- - Net loss for the period (4,801 ) (5,462 ) (6,755 ) (7,760 ) ------------------------------------------------------- - ------ - - ------------- - - ------ - - -------- - Items that may be reclassified subsequently to net loss Exchange differences on translating foreign operations (887 ) 677 (558 ) 948 Comprehensive loss for the period $ (5,688 ) $ (4,785 ) $ (7,313 ) $ (6,812 ) ------------------------------------------------------- - ------ - - ------------- - - ------ - - -------- - Net loss per share Basic and diluted $ (0.31 ) $ (0.43 ) $ (0.44 ) $ (0.62 ) Weighted Average number of common shares outstanding, 12,667,167 15,438,89 12,606,459 basic and diluted 15,440,88 4 8 Note: Prior period results restated to reflect the implementation of IFRS 15 revenue standard.

Hydrogenics Corporation Condensed Interim Consolidated Statements of Cash Flows (in thousands of US dollars) (unaudited) -------------------------------------------------------- ------------------------- - --------------------- Six months ended Three months ended June 30, June 30, 2018 2017 2018 2017 Restated Restated -------------------------------------------------------- - ------ - - -------- - - ------ - - -------- - Cash and cash equivalents provided by (used in): Operating activities Net loss for the period $ (4,801 ) $ (5,462 ) $ (6,755 ) $ (7,760 ) Increase in restricted cash (266 ) (912 ) (279 ) (1,002 ) Items not affecting cash: Loss on disposal of assets 3 3 6 114 Amortization and depreciation 175 202 352 401 Warrants (70 ) 826 (356 ) 1,246 Unrealized foreign exchange gains (179 ) (147 ) (203 ) (133 ) Unrealized loss on joint ventures 1,492 101 1,561 171 Accreted interest 413 629 857 1,141 Stock-based compensation 243 189 465 340 Stock-based compensation - DSUs (62 ) 459 (388 ) 724 Net change in non-cash operating assets and liabilities (1,416 ) 1,584 (859 ) 1,899 -------------------------------------------------------- - ------ - - -------- - - ------ - - -------- - Cash used in operating activities (4,468 ) (2,528 ) (5,599 ) (2,859 ) -------------------------------------------------------- - ------ - - -------- - - ------ - - -------- - Investing activities Investment in joint venture – Enbridge – – – (93 ) Purchase of property, plant and equipment (101 ) (519 ) (335 ) (2,075 ) Receipt of government funding 974 1,492 974 1,851 Proceeds from disposals of property, plant and equipment – – – 1,035 Purchase of intangible assets (1 ) (1 ) (1 ) (1 ) -------------------------------------------------------- - ------ - - -------- - - ------ - - -------- - Cash provided by investing activities 872 972 638 717 -------------------------------------------------------- - ------ - - -------- - - ------ - - -------- - Financing activities Proceeds from common shares issued and stock options 1 19,770 1 19,770 exercised, net of issuance costs Principal repayment of long-term debt (500 ) (250 ) (750 ) (500 ) Interest payment (286 ) (305 ) (582 ) (788 ) Proceeds (repayment) of operating borrowings – (1,449 ) (1,193 ) 190 Repayment of repayable government contributions – (56 ) – (112 ) Cash provided by (used in) financing activities (785 ) 17,710 (2,524 ) 18,560 -------------------------------------------------------- - ------ - - -------- - - ------ - - -------- - Increase (decrease) in cash and cash equivalents during (4,381 ) 16,154 (7,485 ) 16,418 the period Cash and cash equivalents – Beginning of period 18,482 10,608 21,511 10,338 Effect of exchange rate fluctuations on cash and cash (254 ) 399 (179 ) 405 equivalents held -------------------------------------------------------- - ------ - - -------- - - ------ - - -------- - Cash and cash equivalents – End of period $ 13,847 $ 27,161 $ 13,847 $ 27,161 -------------------------------------------------------- - ------ - - -------- - - ------ - - -------- - Note: Prior period results restated to reflect the implementation of IFRS 15 revenue standard.